| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by first author.
Page 6: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1501 | 2 | 2 | 2202 2002 HAUTARZT 53(2):150-151 Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis - Statement | 0 | 0 |
| 1502 | 0 | 1 | 606 1974 ZEITSCHRIFT FUR ENTWICKLUNGSPSYCHOLOGIE UND PADAGOGISCHE PSYCHOLOGIE 6(1):63-65 MERKER H PRENATAL DAMAGE TO CHILDREN WITH RESPECT TO SCHOOL COMMUNITY - HAMBURG MODEL FOR EDUCATION OF THALIDOMIDE DAMAGED CHILDREN - GERMAN - KIRCHHOFF,H | 0 | 0 |
| 1503 | 15 | 59 | 958 1988 ARCHIVES OF TOXICOLOGY 61(3):165-179 MERKER HJ; HEGER W; SAMES K; STURJE H; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE-DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .1. EFFECTS OF 3-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-2,6-DIOXOPIPERIDINE (EM-12) ON SKELETAL DEVELOPMENT | 10 | 18 |
| 1504 | 7 | 17 | 2266 2002 MEDICAL ONCOLOGY 19(2):79-86 Merup M; Kutti J; Birgergard G; Mauritzson N; Bjorkholm M; Markevarn B; Malm C; Westin J; Palmblad J; Samuelsson J; Swedish Natl Study Grp Chronic Mye Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | 4 | 5 |
| 1505 | 0 | 0 | 2341 2003 BLOOD 102(11):33A-33A Mesa RA; Elliott MA; Faoro L; Tefferi A Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: Long term outcome analysis of 2 prospective trials. | 0 | 0 |
| 1506 | 21 | 42 | 2667 2004 MAYO CLINIC PROCEEDINGS 79(7):883-889 Mesa RA; Elliott MA; Schroeder G; Tefferi A Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia | 1 | 1 |
| 1507 | 0 | 0 | 2063 2002 BLOOD 100(11):71A-71A Mesa RA; Li CY; Steensma DP; Pardanani A; Elliott MA; Kaufmann SH; Gray L; Schroeder GS; Tefferi A A combination of low dose thalidomide with prednisone in myelofibrosis with myeloid metaplasia. | 0 | 0 |
| 1508 | 15 | 47 | 2338 2003 BLOOD 101(7):2534-2541 Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder GE; Reeder T; Zeldis JB; Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | 5 | 8 |
| 1509 | 0 | 0 | 221 1963 JOURNAL OF ANATOMY 97(2):308-& METCALF WK THALIDOMIDE, NITRITE SENSITIVITY REACTION AND PYRIDOXINE | 0 | 0 |
| 1510 | 0 | 0 | 222 1963 JOURNAL OF ANATOMY 97(3):479-& METCALF WK THALIDOMIDE, NITRITE SENSITIVITY REACTION AND VITAMIN B COMPLEX | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1511 | 0 | 1 | 223 1963 JOURNAL OF ANATOMY 97(4):638-& METCALF WK METABOLIC DERIVATIVES OF THALIDOMIDE AND HAEMOGLOBIN NITRITE SENSITIVITY REACTION | 0 | 0 |
| 1512 | 13 | 41 | 431 1967 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 9(1):87-& METCALF WK RELATION OF VITAMIN-B COMPLEX TO EFFECT OF THALIDOMIDE ON SENSITIVITY OF INTRACELLULAR HAEMOGLOBIN TO OXIDATION | 0 | 1 |
| 1513 | 4 | 4 | 1179 1995 BRITISH JOURNAL OF DERMATOLOGY 132(1):168-168 MEUNIER L; MARCK Y; RIBEYRE C; MEYNADIER J ADULT CUTANEOUS LANGERHANS CELL HISTIOCYTOSIS - REMISSION WITH THALIDOMIDE TREATMENT | 9 | 20 |
| 1514 | 13 | 34 | 1537 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
| 1515 | 14 | 41 | 1738 2000 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 31 |
| 1516 | 15 | 40 | 2027 2002 ANALYTICAL CHEMISTRY 74(15):3726-3735 Meyring M; Muhlbacher J; Messer K; Kastner-Pustet N; Bringmann G; Mannschreck A; Blaschke G In vitro biotransformation of (R)- and (S)-thalidomide: Application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites | 0 | 2 |
| 1517 | 17 | 32 | 1708 2000 ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 16 |
| 1518 | 10 | 18 | 1560 1999 JOURNAL OF CHROMATOGRAPHY B 723(1-2):255-264 Meyring M; Strickmann D; Chankvetadze B; Blaschke G; Desiderio C; Fanali S Investigation of the in vitro biotransformation of R-(+)- thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS | 8 | 20 |
| 1519 | 1 | 5 | 182 1963 ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA 58(3):355-& MIDTVEDT T EFFECT OF THALIDOMIDE ON GROWTH CURVE OF A RIBOFLAVIN DEPENDENT MICROBE | 0 | 5 |
| 1520 | 8 | 16 | 493 1970 ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA SECTION B- MICROBIOLOGY AND IMMUNOLOGY 78(4):488-& MIDTVEDT T; LINDSTED.G METABOLISM OF THALIDOMIDE IN PSEUDOMONAS-AERUGINOSA NCTC A7244 | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1521 | 0 | 0 | 794 1982 TERATOLOGY 26(1):A17-A17 MIKAMI T; MATSUBARA Y; YAMANAKA H; SUZUKI Y TERATOGENIC EFFECTS OF THALIDOMIDE IN RABBITS - (3) THE DEVELOPMENTAL PROCESSES OF DYSRAPHIC MALFORMATIONS IN JW-NIBS RABBITS | 0 | 0 |
| 1522 | 0 | 0 | 837 1983 TERATOLOGY 28(1):A13-A14 MIKAMI T; MATSUBARA Y; YAMANAKA H; SUZUKI Y TERATOGENIC EFFECTS OF THALIDOMIDE IN RABBITS .4. DYSRAPHISM OF THE ANTERIOR NEUROPORE IN JW-NIBS RABBIT EMBRYOS ANALYZED BY SEM | 0 | 0 |
| 1523 | 18 | 42 | 2340 2003 BLOOD 102(1):69-77 Mileshkin L; Biagi JJ; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Lillie K; Smith JG; Zeldis JB; Prince HM Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age | 7 | 10 |
| 1524 | 1 | 3 | 2422 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):747-748 Mileshkin L; Prince HM; Seymour JF; Biagi JJ Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide | 0 | 0 |
| 1525 | 1 | 34 | 144 1962 LANCET 2(7256):599-& MILLEN JW THALIDOMIDE AND LIMB DEFORMITIES | 0 | 16 |
| 1526 | 4 | 12 | 730 1980 MONATSSCHRIFT KINDERHEILKUNDE 128(1):27-29 MILLER A; SCHMIDT CG; HORWITZ A; KOSENOW W COINCIDENCE OF A THALIDOMIDE-INDUCED MALFORMATION AND A LYMPHOMA OF HIGH MALIGNANCY | 1 | 1 |
| 1527 | 0 | 0 | 1308 1997 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(20):2270-& Miller JL Thalidomide recommended for approval under tight restrictions | 2 | 2 |
| 1528 | 84 | 136 | 1604 1999 TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 5 | 16 |
| 1529 | 7 | 20 | 2209 2002 INTERNATIONAL JOURNAL OF HEMATOLOGY 76(4):365-369 Miller S; Sharda S; Rodrigue J; Mehta P Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life | 0 | 0 |
| 1530 | 4 | 12 | 244 1963 LANCET 2(731):1068-& MILLER ZB INHIBITION OF TISSUE-CULTURE GROWTH BY A SOLUBLE THALIDOMIDE DERIVATIVE | 5 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1531 | 0 | 0 | 817 1983 CLINICAL RESEARCH 31(5):A921-A921 MILLIKAN LE; DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE THE INVITRO EFFECTS OF THALIDOMIDE ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTION | 1 | 1 |
| 1532 | 0 | 0 | 849 1984 CLINICAL RESEARCH 32(2):A603-A603 MILLIKAN LE; DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE THE INVITRO EFFECTS OF THALIDOMIDE ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTION | 0 | 0 |
| 1533 | 2 | 3 | 925 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):283-283 MILLIKAN LE; HASTINGS RC THALIDOMIDE AND LYMPHOCYTE FUNCTION - REPLY | 0 | 1 |
| 1534 | 6 | 6 | 2403 2003 BONE MARROW TRANSPLANTATION 32(3):343-343 Milone JH; Prates V; Bordone J; Napal J; Garcia C Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD | 0 | 0 |
| 1535 | 10 | 18 | 1235 1996 ANTI-CANCER DRUGS 7(3):339-343 Minchinton AI; Fryer KH; Wendt KR; Clow KA; Hayes MMM The effect of thalidomide on experimental tumors and metastases | 29 | 50 |
| 1536 | 0 | 0 | 1620 2000 ANNALS OF ONCOLOGY 11:96-96 Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F; Martinelli G Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis. | 0 | 0 |
| 1537 | 8 | 21 | 2505 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):445-449 Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment | 2 | 2 |
| 1538 | 0 | 0 | 2105 2002 BLOOD 100(11):394A-395A Minnema MM; Fijnheer R; De Groot PG; Lokhorst HM Factor VIII procoagulant activity as risk factor for deep venous thrombosis in patients with Multiple Myeloma during treatment with thalidomide. | 0 | 0 |
| 1539 | 12 | 19 | 2211 2002 INVESTIGATIONAL NEW DRUGS 20(4):389-393 Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L A phase II study of thalidomide in advanced metastatic renal cell carcinoma | 6 | 9 |
| 1540 | 11 | 16 | 1231 1996 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 53(4):429-431 Minor JR; Piscitelli SC Thalidomide in diseases associated with human immunodeficiency virus infection | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1541 | 0 | 1 | 708 1979 NEW REPUBLIC 180(16):30-32 MINTZ M SUFFER THE CHILDREN - STORY OF THALIDOMIDE BY THE INSIGHT TEAM OF THE SUNDAY-TIMES OF LONDON | 0 | 0 |
| 1542 | 0 | 0 | 638 1977 ACTA PHYSIOLOGICA LATINOAMERICANA 27(6):377-378 MIRANDA RO; HASTINGS RC THALIDOMIDE INHIBITION OF ANTIBODY-SYNTHESIS | 0 | 0 |
| 1543 | 3 | 3 | 1094 1993 CLINICAL AND EXPERIMENTAL DERMATOLOGY 18(5):487-487 MISERY L; LARBRE B; LYONNET S; FAURE M; THIVOLET J REMISSION OF LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE TREATMENT | 11 | 18 |
| 1544 | 5 | 6 | 1182 1995 CLINICAL AND EXPERIMENTAL DERMATOLOGY 20(1):85-85 MISERY L; PEGUETNAVARRO J; THIVOLET J; FAURE M; SCHMITT D; CLAUDY AL THALIDOMIDE DOES NOT AFFECT IN-VITRO MIXED SKIN CELL LYMPHOCYTE REACTIONS | 0 | 1 |
| 1545 | 0 | 0 | 476 1969 ANATOMICAL RECORD 163(2):230-& MITCHELL JT STUDIES WITH THALIDOMIDE AND RELATED COMPOUNDS ON EARLY DEVELOPING MOUSE EMBRYOS | 0 | 0 |
| 1546 | 0 | 0 | 495 1970 ANATOMICAL RECORD 166(2):349-& MITCHELL JT THALIDOMIDE-INDUCED MALFORMATIONS IN EMBRYO OF COMMON SNAPPING TURTLE, CHELYDRA SERPENTINA | 0 | 0 |
| 1547 | 0 | 0 | 609 1975 ANATOMICAL RECORD 181(2):428-429 MITCHELL JT COMPARATIVE TERATOGENIC EFFECTS OF MALATHION, CAPTAN, AND THALIDOMIDE IN EMBRYO OF COMMON SNAPPING TURTLE, CHELYDRA-SERPENTINA | 0 | 1 |
| 1548 | 0 | 0 | 1953 2001 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 286(8):909-909 Mitka M Thalidomide battles myeloma | 1 | 0 |
| 1549 | 0 | 0 | 2393 2003 BLOOD 102(11):903A-903A Mitsiades CS; Mitsiades N; McMullan CJ; Poulaki V; Shringarpure R; Hideshima T; Chauhan D; Treon SP; Richardson PG; Munshi NC; Joseph M; Libermann TA; Anderson KC Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstrom's macroglobulinemia. | 0 | 0 |
| 1550 | 0 | 0 | 1873 2001 BLOOD 98(11):775A-775A Mitsiades N; Mitsiades CS; Poulaki V; Akiyama M; Tai YT; Lin BK; Hayashi T; Catley L; Hideshima T; Chauhan D; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1551 | 12 | 35 | 2057 2002 BLOOD 99(12):4525-4530 Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | 13 | 53 |
| 1552 | 3 | 11 | 502 1970 EXPERIENTIA 26(3):305-& MIURA M; WUEST H POTENTIATING EFFECT OF THALIDOMIDE ON METHYLCHOLANTHRENE ONCOGENESIS IN MICE | 2 | 5 |
| 1553 | 5 | 21 | 1244 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 224(2):426-430 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production | 15 | 25 |
| 1554 | 7 | 14 | 1245 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 226(2):439-444 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence | 13 | 20 |
| 1555 | 2 | 3 | 876 1985 ARTHRITIS AND RHEUMATISM 28(7):836-836 MIYACHI Y A POSSIBLE MECHANISM OF ACTION OF THALIDOMIDE ON RHEUMATOID-ARTHRITIS | 5 | 5 |
| 1556 | 2 | 9 | 893 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(2):304-305 MIYACHI Y; NIWA Y THALIDOMIDE AND OXYGEN INTERMEDIATES | 0 | 0 |
| 1557 | 6 | 25 | 774 1982 ARCHIVES OF DERMATOLOGICAL RESEARCH 274(3-4):363-367 MIYACHI Y; OZAKI M; UCHIDA K; NIWA Y EFFECTS OF THALIDOMIDE ON THE GENERATION OF OXYGEN INTERMEDIATES BY ZYMOSAN-STIMULATED NORMAL POLYMORPHONUCLEAR LEUKOCYTES | 13 | 21 |
| 1558 | 0 | 0 | 2450 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Miyata M CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation - Reply | 0 | 0 |
| 1559 | 21 | 37 | 2449 2003 DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
| 1560 | 0 | 0 | 2391 2003 BLOOD 102(11):692A-692A Moehler T; Hillengass J; Gerull S; Benner A; Schlenzka J; Neben K; Egerer G; Schaefer H; Goerner M; He AD Thalidomide (T) and CED chemotherapy followed by stem cell transplantation for poor prognosis multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1561 | 3 | 19 | 1878 2001 BLOOD 98(13):3846-3848 Moehler TM; Neben K; Benner A; Egerer G; Krasniqi F; Ho AD; Goldschmidt H Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy | 13 | 21 |
| 1562 | 0 | 0 | 1501 1999 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
| 1563 | 0 | 0 | 1652 2000 BLOOD 96(11):290B-290B Moehler TM; Neben K; Hawighorst H; Egerer G; van Kaick G; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. | 0 | 5 |
| 1564 | 0 | 0 | 1869 2001 BLOOD 98(11):395B-395B Moehler TM; Neben K; Kasper B; Kordelas L; Egerer G; Goerner M; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as remission induction regimen for poor prognosis multiple myeloma patients before autologous or allogeneic stem cell transplantation. | 0 | 0 |
| 1565 | 0 | 0 | 2103 2002 BLOOD 100(11):393B-393B Moehler TM; Schlenzka J; Kasper B; Neben K; Egerer G; Ho AD; Goldschmidt H Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. | 0 | 0 |
| 1566 | 8 | 16 | 458 1968 CHEMICAL & PHARMACEUTICAL BULLETIN 16(11):2289-& MOHRI T; KITAGAWA H NEGATIVE EFFECT OF THALIDOMIDE AND RELATIVE SUBSTANCES ON GROWTH OF HELA CELLS | 0 | 1 |
| 1567 | 0 | 0 | 2184 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Mohty M; Blaise D; Isnardon D; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 1568 | 0 | 0 | 2127 2002 BONE MARROW TRANSPLANTATION 29:S100-S100 Mohty M; Stoppa A; Blaise D; Isnardon D; Gastaut J; Olive D; Gaugler B Differential regulation of dendritic cell function by the Immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 1569 | 23 | 30 | 2236 2002 JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945 Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide | 2 | 6 |
| 1570 | 0 | 0 | 1860 2001 BLOOD 98(11):310B-310B Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: Implications for multiple myeloma therapy. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1571 | 4 | 6 | 1055 1992 BRITISH JOURNAL OF DERMATOLOGY 126(1):92-93 MOISSON YF; JANIER M; CIVATTE J THALIDOMIDE FOR RECURRENT ERYTHEMA MULTIFORME | 9 | 12 |
| 1572 | 11 | 30 | 1357 1997 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
| 1573 | 18 | 29 | 1980 2001 MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 11 | 16 |
| 1574 | 15 | 35 | 1600 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):305-311 Monastirli A; Georgiou S; Bolsen K; Pasmatzi E; Papapanagiotou A; Goerz G; Kalofoutis A; Merk HF; Tsambaos D Treatment of porphyria cutanea tarda with oral thalidomide | 5 | 6 |
| 1575 | 5 | 20 | 890 1985 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 53(2):201-205 MONCADA B; BARANDA ML; GONZALEZAMARO R; URBINA R; LOREDO CE THALIDOMIDE - EFFECT ON T-CELL SUBSETS AS A POSSIBLE MECHANISM OF ACTION | 31 | 42 |
| 1576 | 0 | 0 | 815 1983 CLINICAL RESEARCH 31(2):A266-A266 MONCADA B; BARANDA ML; LOREDO C; URBINA R; GONZALEZAMARO R; HERNANDEZRODRIGUEZ H THALIDOMIDE AND LEPRA REACTION - DOES THE DRUG AFFECT LYMPHOCYTE POPULATIONS | 0 | 0 |
| 1577 | 13 | 20 | 369 1966 CANADIAN MEDICAL ASSOCIATION JOURNAL 95(9):390-& MONGEAU M; GINGRAS G; SHERMAN ED; HEBERT B; HUTCHISO.J; CORRIVEA.C MEDICAL AND PSYCHOSOCIAL ASPECTS OF HABILITATION OF THALIDOMIDE CHILDREN | 0 | 2 |
| 1578 | 7 | 12 | 2661 2004 LEUKEMIA & LYMPHOMA 45(8):1711-1712 Montagut C; Bosch F; Villela L; Rosinol L; Blade J Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide | 0 | 0 |
| 1579 | 0 | 1 | 516 1971 BRITISH JOURNAL OF EDUCATIONAL PSYCHOLOGY 41(N):347-347 MOORE EM CHALLENGE OF THALIDOMIDE - PRINGLE,MLK AND FIDDES,DO | 0 | 0 |
| 1580 | 0 | 0 | 267 1964 ANATOMICAL RECORD 148(2):313-& MOORE KL; DWORNIK JJ; DALTON RD CONGENITAL DEFECTS PRODUCED IN RAT BY THALIDOMIDE | 2 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1581 | 1 | 1 | 1575 1999 LANCET 353(9163):1503-1503 Moore P Thalidomide's teratogenic mechanism starts to yield to study | 0 | 0 |
| 1582 | 14 | 27 | 2680 2004 ONCOLOGY REPORTS 11(1):93-95 Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma | 0 | 0 |
| 1583 | 35 | 44 | 1804 2001 AMERICAN JOURNAL OF THE MEDICAL SCIENCES 321(5):321-326 Moraes M; Russo G Thalidomide and its dermatologic uses | 3 | 9 |
| 1584 | 0 | 0 | 701 1979 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 47(2):395-396 MORALES MJ; SHANNON EJ; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY MECHANISM OF ACTION OF THALIDOMIDE IN LEPROSY | 0 | 0 |
| 1585 | 12 | 43 | 1303 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(10):857-863 Moreira AL; Corral LG; Ye WG; Johnson B; Stirling D; Muller GW; Freedman VH; Kaplan G Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro | 36 | 47 |
| 1586 | 10 | 28 | 1567 1999 JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 36 |
| 1587 | 8 | 14 | 1441 1998 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 66(1):61-65 Moreira AL; Kaplan G; Villahermosa LG; Fajardo TJ; Abalos RM; Cellona RV; Balagon MVF; Tan EV; Walsh GP Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL | 1 | 9 |
| 1588 | 1 | 19 | 1100 1993 JOURNAL OF EXPERIMENTAL MEDICINE 177(6):1675-1680 MOREIRA AL; SAMPAIO EP; ZMUIDZINAS A; FRINDT P; SMITH KA; KAPLAN G THALIDOMIDE EXERTS ITS INHIBITORY-ACTION ON TUMOR-NECROSIS-FACTOR-ALPHA BY ENHANCING MESSENGER-RNA DEGRADATION | 231 | 424 |
| 1589 | 6 | 28 | 1390 1997 TUBERCLE AND LUNG DISEASE 78(1):47-55 Moreira AL; Tsenova-Berkova L; Wang J; Laochumroonvorapong P; Freeman S; Freedman VH; Kaplan G Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis | 21 | 46 |
| 1590 | 6 | 35 | 1318 1997 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 30(10):1199-1207 Moreira AL; Wang J; Sarno EN; Kaplan G Thalidomide protects mice against LPS-induced shock | 11 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1591 | 0 | 0 | 2066 2002 BLOOD 100(11):96A-96A Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). | 0 | 1 |
| 1592 | 2 | 3 | 2539 2003 NEW ENGLAND JOURNAL OF MEDICINE 348(18):1821-1822 Morgan AE; Smith WK; Levenson JL Reversible dementia due to thalidomide therapy for multiple myeloma | 1 | 1 |
| 1593 | 1 | 1 | 59 1962 BRITISH MEDICAL JOURNAL (5280):792-& MORGAN BC THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 1 | 2 |
| 1594 | 0 | 0 | 380 1966 FEDERATION PROCEEDINGS 25(2P1):532-& MORI A; NYHAN WL; ASHIDA H METABOLISM OF THALIDOMIDE IN PREGNANT RATS | 4 | 5 |
| 1595 | 0 | 0 | 2599 2004 BRITISH JOURNAL OF HAEMATOLOGY 125:20-20 Morris TCM; Hull DR; Boyd C; Jones FCG; Kettle PJ; Drake M; McLoughlin R; Quinn J Clarithromycin, dexamethasone and low dose thalidomide (CDT) is effective therapy in relapsed/refractory myeloma and useful in patients with cytopenias | 0 | 0 |
| 1596 | 6 | 20 | 2219 2002 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306 Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M Phase II trial of thalidomide for patients with advanced renal cell carcinoma | 20 | 34 |
| 1597 | 3 | 17 | 799 1983 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 110(8):611-614 MOULIN G; BONNET F; BARRUT D; FRANC MP TREATMENT OF JESSNER-KANOF DISEASE WITH THALIDOMIDE | 12 | 21 |
| 1598 | 0 | 0 | 2455 2003 EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
| 1599 | 0 | 0 | 2345 2003 BLOOD 102(11):149B-149B Moutouh-de Parseval LA; Glezer E; Corral L; Muller G; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cells developmental pathway. | 0 | 0 |
| 1600 | 2 | 2 | 393 1966 LANCET 1(7442):882-& MOUZAS GL ANOTHER CHANCE FOR THALIDOMIDE | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1601 | 5 | 8 | 473 1968 TRANSPLANTATION 6(3):476-& MOUZAS GL; GERSHON RK EFFECT OF THALIDOMIDE ON SKIN ALLOGRAFTS IN MICE - SURVIVAL OF GRAFTS | 8 | 9 |
| 1602 | 0 | 0 | 743 1981 ARCHIVES OF GYNECOLOGY 232(1-4):611-612 MUHLENSTEDT D; SCHWARZ M GYNECOLOGICAL-ENDOCRINOLOGICAL STUDIES ON THALIDOMIDE-DAMAGED GIRLS | 1 | 1 |
| 1603 | 2 | 33 | 852 1984 GEBURTSHILFE UND FRAUENHEILKUNDE 44(4):243-248 MUHLENSTEDT D; SCHWARZ M GYNECOLOGICAL AND ENDOCRINOLOGICAL INVESTIGATIONS IN WOMEN DAMAGED BY THALIDOMIDE | 0 | 0 |
| 1604 | 61 | 107 | 2169 2002 CROATIAN MEDICAL JOURNAL 43(3):274-285 Mujagic H; Chabner BA; Mujagic Z Mechanisms of action and potential therapeutic uses of thalidomide | 1 | 2 |
| 1605 | 14 | 21 | 1322 1997 CHEMTECH 27(1):21-25 Muller GW Thalidomide: From tragedy to new drug discovery | 4 | 9 |
| 1606 | 17 | 26 | 1279 1996 JOURNAL OF MEDICINAL CHEMISTRY 39(17):3238-3240 Muller GW; Corral LG; Shire MG; Wang H; Moreira A; Kaplan G; Stirling DI Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity | 33 | 48 |
| 1607 | 4 | 13 | 1592 1999 ORGANIC PROCESS RESEARCH & DEVELOPMENT 3(2):139-140 Muller GW; Konnecke WE; Smith AM; Khetani VD A concise two-step synthesis of thalidomide | 5 | 12 |
| 1608 | 4 | 13 | 1409 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(19):2669-2674 Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen YX; Stirling DI Thalidomide analogs and PDE4 inhibition | 20 | 31 |
| 1609 | 0 | 0 | 1634 2000 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
| 1610 | 0 | 0 | 87 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(14):665-& MUNN JD THALIDOMIDE AND CONGENITAL MALFORMATIONS | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1611 | 5 | 17 | 966 1988 CLINICAL AND EXPERIMENTAL DERMATOLOGY 13(6):408-410 MUNRO CS; COX NH PYODERMA GANGRENOSUM ASSOCIATED WITH BEHCETS SYNDROME - RESPONSE TO THALIDOMIDE | 12 | 19 |
| 1612 | 0 | 1 | 693 1979 BRITISH MEDICAL JOURNAL 1(6178):1625-1625 MUNRO I THALIDOMIDE AND THE LANCET | 0 | 0 |
| 1613 | 0 | 0 | 1516 1999 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
| 1614 | 3 | 15 | 1786 2000 SEMINARS IN HEMATOLOGY 37(1):15-21 Munshi NC; Desikan KR; Barlogie B Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies | 5 | 6 |
| 1615 | 14 | 33 | 2453 2003 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
| 1616 | 0 | 0 | 1945 2001 HEPATOLOGY 34(4):279A-279A Muriel P; Fernandez-Martinez E; Perez-Alvarez VM; Morales-Rios MS A thalidomide analog with hepatoprotective and antifibrotic properties in biliary obstruction-induced cirrhosis in the rat. | 0 | 0 |
| 1617 | 0 | 0 | 1947 2001 HEPATOLOGY 34(4):517A-517A Muriel P; Garcia JC; Ponce S; Perez-Alvarez VM; Fernandez-Martinez E; Morales-Rios MS Synthesis and pharmacological evaluation of a thalidomide analog, the 3-phthalimido-3-(3,4-dimethoxyphenyl)propanoic acid in liver cirrhosis induced by bile duct ligation in the rat. | 0 | 0 |
| 1618 | 0 | 0 | 1946 2001 HEPATOLOGY 34(4):516A-516A Muriel P; Ponce S; Garcia JC Thalidomide partially prevents CCl4-induced liver cirrhosis. | 0 | 0 |
| 1619 | 1 | 5 | 643 1977 BRITISH MEDICAL JOURNAL 2(6096):1191-1191 MURPHY R; MOHR P 2 CONGENITAL NEUROLOGICAL ABNORMALITIES CAUSED BY THALIDOMIDE | 2 | 2 |
| 1620 | 15 | 59 | 2662 2004 LEUKEMIA RESEARCH 28(4):325-332 Musto P Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1621 | 0 | 0 | 2359 2003 BLOOD 102(11):382B-382B Musto P; Bodenizza C; Falcone A; Sanpaolo G; Cascavilla N; Melillo L; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Scalzulli PR; Greco MM; Carella AM; Beltrami G; Carella AM Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate. | 0 | 1 |
| 1622 | 0 | 0 | 1870 2001 BLOOD 98(11):622A-622A Musto P; Falcone A; Bodenizza C; Sanpaolo G; Matera R; Bisceglia M; Carella AM Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS): Relationship to serum and marrow levels of angiogenetic growth factors (AGF). | 0 | 3 |
| 1623 | 3 | 10 | 2200 2002 HAEMATOLOGICA 87(8):884-886 Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes | 1 | 1 |
| 1624 | 0 | 0 | 2078 2002 BLOOD 100(11):336B-336B Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM Does thalidomide act with different mechanisms of action in myelodysplastic syndromes? | 0 | 0 |
| 1625 | 0 | 0 | 2350 2003 BLOOD 102(11):327B-328B Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Carella AM Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. | 0 | 0 |
| 1626 | 0 | 0 | 2095 2002 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
| 1627 | 1 | 1 | 1686 2000 BRITISH JOURNAL OF HAEMATOLOGY 111(3):986-986 Myers B; Crouch D; Dolan G Thalidomide treatment in advanced refractory myeloma | 5 | 5 |
| 1628 | 4 | 4 | 2138 2002 BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347 Myers B; Dolan G Analysis of durability of response to thalidomide treatment for relapsed myeloma patients | 1 | 1 |
| 1629 | 3 | 4 | 1890 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(1):234-234 Myers B; Grimley C; Crouch D; Dolan G Lack of response to thalidomide in plasmacytomas | 2 | 4 |
| 1630 | 1 | 3 | 1889 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):245-245 Myers B; Grimley C; Dolan G Thalidomide and low-dose dexamethasone in myeloma treatment | 2 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1631 | 0 | 0 | 2075 2002 BLOOD 100(11):211A-211A Myers B; Jones SG; McMillan AK; Dolan G Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. | 0 | 0 |
| 1632 | 0 | 0 | 2356 2003 BLOOD 102(11):380B-380B Myers B; Russell NH; McMillan AK Use of a novel combination chemotherapy for AL-amyloidosis: Cyclophosphamide, thalidomide and dexamethasone - Serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. | 0 | 0 |
| 1633 | 10 | 51 | 1899 2001 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
| 1634 | 0 | 0 | 2514 2003 LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
| 1635 | 3 | 8 | 779 1982 BRITISH JOURNAL OF DERMATOLOGY 107(1):83-86 NAAFS B; BAKKERS EJM; FLINTERMAN J; FABER WR THALIDOMIDE TREATMENT OF SUB-ACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS | 30 | 44 |
| 1636 | 2 | 3 | 806 1983 BRITISH JOURNAL OF DERMATOLOGY 109(4):479-480 NAAFS B; FABER WR THALIDOMIDE | 0 | 0 |
| 1637 | 16 | 24 | 886 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(2):131-134 NAAFS B; FABER WR THALIDOMIDE THERAPY - AN OPEN TRIAL | 27 | 36 |
| 1638 | 0 | 0 | 253 1963 POULTRY SCIENCE 42(5):1293-& NABER EC; LARGENT EJ MALFORMATIONS INDUCED BY THALIDOMIDE IN DEVELOPING CHICK EMBRYO | 0 | 1 |
| 1639 | 13 | 27 | 351 1965 POULTRY SCIENCE 44(6):1583-& NABER EC; LARGENT EJ THALIDOMIDE TERATOGENESIS IN DEVELOPING CHICK EMBRYO AND ITS RELATIONSHIP TO VITAMIN METABOLISM | 1 | 2 |
| 1640 | 5 | 17 | 2609 2004 CHIRALITY 16:S36-S39 Nakanishi T; Yamakawa N; Asahi T; Shibata N; Ohtani B; Osaka T Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1641 | 1 | 11 | 2533 2003 MEDICAL HYPOTHESES 60(4):513-514 Namazi MR The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata | 0 | 0 |
| 1642 | 2 | 25 | 2278 2002 PEDIATRIC RESEARCH 52(4):576-579 Narita N; Kato M; Tazoe M; Miyazaki K; Narita M; Okado N Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: Putative animal models for autism | 0 | 3 |
| 1643 | 4 | 10 | 239 1963 LANCET 1(729):1374-& NARROD SA; KING CTG METABOLIC STUDIES WITH THALIDOMIDE | 4 | 9 |
| 1644 | 156 | 187 | 2317 2003 ANNALS OF PHARMACOTHERAPY 37(9):1307-1320 Nasca MR; Micali G; Cheigh NH; West LE; West DP Dermatologic and nondermatologic uses of thalidomide | 1 | 1 |
| 1645 | 27 | 52 | 1566 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 14 |
| 1646 | 0 | 0 | 1358 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):179-179 Nasca MR; OToole EA; Palicharla P; West DP; Woodley DT Thalidomide increases both human keratinocyte proliferation and migration | 0 | 0 |
| 1647 | 2 | 9 | 405 1966 NATURWISSENSCHAFTEN 53(11):275-& NATARAJA.AT; NILSSON R STUDIES ON CYTOLOGICAL EFFECTS OF THALIDOMIDE AND ITS HYDROLYTIC PRODUCTS | 0 | 7 |
| 1648 | 4 | 4 | 2221 2002 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430 Nathan PD; Gore ME; Eisen TG Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma | 7 | 11 |
| 1649 | 5 | 10 | 1187 1995 DIGESTIVE DISEASES AND SCIENCES 40(5):1147-1148 NAUM SM; MOLLOY PJ; KANIA RJ; MCGARR J; VANTHIEL DH USE OF THALIDOMIDE IN TREATMENT AND MAINTENANCE OF IDIOPATHIC ESOPHAGEAL ULCERS IN HIV+ INDIVIDUALS | 7 | 11 |
| 1650 | 0 | 6 | 2163 2002 CLINICAL CANCER RESEARCH 8(8):2751-2751 Neben K Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1651 | 0 | 0 | 1500 1999 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
| 1652 | 17 | 24 | 2164 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
| 1653 | 0 | 0 | 1635 2000 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
| 1654 | 13 | 35 | 1907 2001 CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
| 1655 | 3 | 12 | 1893 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(3):605-608 Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion | 19 | 29 |
| 1656 | 0 | 0 | 1844 2001 BLOOD 98(11):163A-163A Neben K; Moehler TM; Benner A; Kraemer A; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). | 0 | 0 |
| 1657 | 0 | 0 | 2070 2002 BLOOD 100(11):170A-170A Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma. | 0 | 0 |
| 1658 | 0 | 0 | 1876 2001 BLOOD 98(11):849A-849A Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Goldschmidt H Genetic polymorphism in the tumor necrosis factor-alpha locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma (MM). | 0 | 1 |
| 1659 | 4 | 20 | 2060 2002 BLOOD 100(6):2263-2265 Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma | 9 | 19 |
| 1660 | 1 | 1 | 927 1986 LEPROSY REVIEW 57(3):273-273 NEELAMKAVIL P SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1661 | 7 | 11 | 1389 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):R1-R2 Neubert D Never-ending tales of the mode of the teratogenic action of thalidomide | 3 | 5 |
| 1662 | 3 | 46 | 959 1988 ARCHIVES OF TOXICOLOGY 61(3):180-191 NEUBERT D; HEGER W; MERKER HJ; SAMES K; MEISTER R EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .2. ELUCIDATION OF THE SUSCEPTIBLE PERIOD AND OF THE VARIABILITY OF EMBRYONIC STAGES | 8 | 21 |
| 1663 | 0 | 0 | 509 1970 NAUNYN-SCHMIEDEBERGS ARCHIV FUR PHARMAKOLOGIE 266(4-5):408-& NEUBERT D; KOHLER E HYPOTHETICAL EXPLANATION OF EMBRYTOXIC ACTION OF THALIDOMIDE | 2 | 3 |
| 1664 | 0 | 0 | 535 1971 TERATOLOGY 4(4):495-& NEUBERT D; TESKE S; ENGELS K INHIBITION OF PROTOCOLLAGEN PROLINHYDROXYLASE BY HYDROLYSIS PRODUCTS OF THALIDOMIDE | 0 | 0 |
| 1665 | 7 | 45 | 1153 1994 LIFE SCIENCES 56(6):407-420 NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .4. DOWN-REGULATION OF THE CD26 RECEPTOR, PROBABLY INVOLVED IN THE BINDING OF HIV COMPONENTS TO T-CELLS IN PRIMATES | 3 | 4 |
| 1666 | 18 | 38 | 1210 1995 LIFE SCIENCES 58(4):295-316 Neubert R; Hinz N; Thiel R; Neubert D Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide | 3 | 7 |
| 1667 | 4 | 11 | 1582 1999 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
| 1668 | 11 | 27 | 1069 1992 LIFE SCIENCES 51(26):2107-2116 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .2. CHANGES IN RECEPTORS ON BLOOD-CELLS OF A HEALTHY VOLUNTEER | 32 | 38 |
| 1669 | 50 | 89 | 1087 1993 ARCHIVES OF TOXICOLOGY 67(1):1-17 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE DERIVATIVES AND THE IMMUNE-SYSTEM .1. CHANGES IN THE PATTERN OF INTEGRIN RECEPTORS AND OTHER SURFACE-MARKERS ON LYMPHOCYTE-T SUBPOPULATIONS OF MARMOSET BLOOD | 40 | 49 |
| 1670 | 2 | 14 | 42 1961 DISEASES OF THE NERVOUS SYSTEM 22(1):52-& NEUHAUS G; IBE K SURVIVAL FOLLOWING OVERDOSE OF THALIDOMIDE | 5 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1671 | 0 | 3 | 921 1986 FOOD AND CHEMICAL TOXICOLOGY 24(6-7):635-636 NEWALL DR; TESH JM EMBRYO CULTURE AS AN EARLY SCREEN FOR TERATOGENIC POTENTIAL .2. THALIDOMIDE | 0 | 2 |
| 1672 | 4 | 12 | 655 1977 PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON 70(4):225-227 NEWMAN CGH CLINICAL OBSERVATIONS ON THALIDOMIDE SYNDROME | 0 | 13 |
| 1673 | 13 | 38 | 909 1985 TERATOLOGY 32(1):133-144 NEWMAN CGH TERATOGEN UPDATE - CLINICAL ASPECTS OF THALIDOMIDE EMBRYOPATHY - A CONTINUING PREOCCUPATION | 8 | 27 |
| 1674 | 11 | 35 | 918 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
| 1675 | 0 | 0 | 873 1985 AMERICAN JOURNAL OF PRIMATOLOGY 8(4):355-355 NEWMAN L; HENDERICKX A INTERSPECIES VARIATION IN FETAL OTOTEMPOROMANDIBULAR ANOMALIES FOLLOWING MATERNAL THALIDOMIDE EXPOSURE | 0 | 0 |
| 1676 | 0 | 0 | 797 1983 AMERICAN JOURNAL OF PRIMATOLOGY 4(4):336-336 NEWMAN L; HENDRICKX A FETAL DEVELOPMENT IN THE NORMAL AND THALIDOMIDE-EXPOSED THICK-TAILED BUSHBABY | 0 | 0 |
| 1677 | 0 | 0 | 639 1977 ANATOMICAL RECORD 187(4):667-668 NEWMAN LM STRUCTURAL EAR MALFORMATIONS INDUCED BY THALIDOMIDE IN FETAL BONNET MONKEY (M-RADIATA) | 0 | 0 |
| 1678 | 4 | 40 | 769 1981 TERATOLOGY 23(3):351-364 NEWMAN LM; HENDRICKX AG FETAL EAR MALFORMATIONS INDUCED BY MATERNAL INGESTION OF THALIDOMIDE IN THE BONNET MONKEY (MACACA, RADIATA) | 2 | 13 |
| 1679 | 3 | 20 | 891 1985 JOURNAL OF CRANIOFACIAL GENETICS AND DEVELOPMENTAL BIOLOGY 5(2):147-157 NEWMAN LM; HENDRICKX AG TEMPOROMANDIBULAR MALFORMATIONS IN THE BONNET MONKEY (MACACA-RADIATA) FETUS FOLLOWING MATERNAL INGESTION OF THALIDOMIDE | 0 | 4 |
| 1680 | 0 | 1 | 1531 1999 CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1681 | 32 | 45 | 2048 2002 BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
| 1682 | 21 | 31 | 2429 2003 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 3 | 5 |
| 1683 | 0 | 0 | 2178 2002 EUROPEAN JOURNAL OF CANCER 38:S82-S82 Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD In vitro antiangiogenic activity of thalidomide analogues | 0 | 0 |
| 1684 | 10 | 20 | 2611 2004 CLINICAL CANCER RESEARCH 10(12):4192-4197 Ng SSW; Macpherson GR; Gutschow M; Eger K; Figg WD Antitumor effects of thalidomide analogs in human prostate cancer Xenografts implanted in immunodeficient mice | 0 | 0 |
| 1685 | 12 | 21 | 1345 1997 INTERNATIONAL JOURNAL OF ONCOLOGY 10(5):965-969 Nguyen M; Tran C; Barsky S; Sun JR; McBride W; Pegram M; Pietras R; Love S; Glaspy J Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies | 20 | 26 |
| 1686 | 27 | 45 | 2648 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
| 1687 | 8 | 13 | 386 1966 JOURNAL OF PHARMACY AND PHARMACOLOGY 18(1):46-& NICHOLLS PJ A NOTE ON ABSORPTION AND EXCRETION OF 14C-LABELLED THALIDOMIDE IN PREGNANT MICE | 7 | 7 |
| 1688 | 14 | 27 | 1314 1997 BIOCHEMICAL PHARMACOLOGY 53(10):1553-1557 Nicolai S; Sies H; Stahl W Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts | 6 | 11 |
| 1689 | 6 | 13 | 1010 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(11):1054-1056 NICOLAU DP; WEST TE THALIDOMIDE - TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN PATIENTS WITH AIDS | 9 | 17 |
| 1690 | 1 | 4 | 857 1984 LANCET 2(8394):98-99 NIELSEN H; BENNIKE T THALIDOMIDE ENHANCES DEFECTIVE MONOCYTE FUNCTION IN LEPROMATOUS LEPROSY | 6 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1691 | 6 | 14 | 910 1986 ACTA PATHOLOGICA MICROBIOLOGICA ET IMMUNOLOGICA SCANDINAVICA SECTION C-IMMUNOLOGY 94(6):233-237 NIELSEN H; VALERIUS NH THALIDOMIDE ENHANCES SUPEROXIDE ANION RELEASE FROM HUMAN POLYMORPHONUCLEAR AND MONONUCLEAR LEUKOCYTES | 4 | 7 |
| 1692 | 0 | 0 | 2348 2003 BLOOD 102(11):237A-237A Niesvizky R; Pekle K; Lyons L; Pearse RN; Bergsagel PL; Schuster MW; Cho HJ; Leonard JP; Coleman M Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin(TM)) on response rate. interim results of a prospective, sequential, randomized trial. | 0 | 0 |
| 1693 | 0 | 0 | 1350 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(5):379-379 Nightingale SL Workshop on thalidomide | 0 | 0 |
| 1694 | 0 | 0 | 1443 1998 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
| 1695 | 11 | 26 | 2171 2002 DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
| 1696 | 0 | 0 | 1612 2000 AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
| 1697 | 6 | 11 | 1120 1994 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 199(2):455-460 NISHIMURA K; HASHIMOTO Y; IWASAKI S ENHANCEMENT OF PHORBOL ESTER-INDUCED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE | 26 | 43 |
| 1698 | 7 | 20 | 1408 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(9):1071-1076 Niwayama S; Loh C; Turk BE; Liu JO; Miyachi H; Hashimoto Y Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action | 8 | 10 |
| 1699 | 0 | 0 | 1223 1996 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 212:140-MEDI Niwayama S; Turk B; Liu J Potent inhibition of tumor necrosis factor-alpha by tetrafluoro-thalidomide and tetrafluorophthalimides | 0 | 0 |
| 1700 | 6 | 31 | 2587 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(16):4141-4145 Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y Phenylhomophthalimide-type NOS inhibitors derived from thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1701 | 8 | 30 | 2051 2002 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046 Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y Thalidomide and its analogues as cyclooxygenase inhibitors | 9 | 11 |
| 1702 | 14 | 24 | 1211 1995 LIFE SCIENCES 58(4):337-348 Nogueira AC; Neubert R; Felies A; JacobMuller U; Frankus E; Neubert D Thalidomide derivatives and the immune system .6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets | 2 | 3 |
| 1703 | 10 | 27 | 1152 1994 LIFE SCIENCES 55(2):77-92 NOGUEIRA AC; NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS | 56 | 63 |
| 1704 | 0 | 0 | 1699 2000 CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| 1705 | 25 | 30 | 1481 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
| 1706 | 0 | 0 | 801 1983 AUSTRALIAN PAEDIATRIC JOURNAL 19(3):198-198 NORTH K; MCCREDIE J THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 0 | 0 |
| 1707 | 3 | 4 | 798 1983 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 110(6-7):551-552 NOUGUE J; NOUGUE M; BAZEX J; HAYEK JP; BIDOUZE H OCCURRENCE OF A GENITAL HEMORRHAGIC DURING A THALIDOMIDE TREATED PRURIGO NODULARIS | 3 | 3 |
| 1708 | 0 | 0 | 2360 2003 BLOOD 102(11):382B-382B Novoselac AV; Reddy S; Ohsumi F; Sherman RE; Samaha S Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide. | 0 | 0 |
| 1709 | 4 | 22 | 335 1965 HUMANGENETIK 1(6):516-536 NOWACK E CORRELATION BETWEEN THE PERIOD OF THALIDOMIDE-ADMINISTRATION AND EMBRYOPATHY | 19 | 40 |
| 1710 | 14 | 36 | 534 1971 TERATOLOGY 4(4):409-& NUDLEMAN KL; TRAVILL AA MORPHOLOGICAL AND HISTOCHEMICAL STUDY OF THALIDOMIDE-INDUCED UPPER LIMB MALFORMATIONS IN RABBIT FETUSES | 3 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1711 | 2 | 13 | 11 1961 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 81(6):1245-& NULSEN RO TRIAL OF THALIDOMIDE IN INSOMNIA ASSOCIATED WITH THIRD TRIMESTER | 1 | 1 |
| 1712 | 0 | 1 | 4 1959 BRITISH MEDICAL JOURNAL 2(OCT31):888-888 NYAZAI AKK THALIDOMIDE | 1 | 2 |
| 1713 | 0 | 0 | 259 1963 SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 15(1):102-& NYSTROM C BIOCHEMICAL EFFECTS OF THALIDOMIDE - A PRELIMINARY REPORT | 8 | 12 |
| 1714 | 0 | 0 | 2110 2002 BLOOD 100(11):402A-402A Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. | 0 | 2 |
| 1715 | 2 | 4 | 216 1963 EXPERIENTIA 19(12):645-& OBBINK HJK; DALDERUP LM EFFECTS OF THALIDOMIDE IN RAT FOETUS | 0 | 7 |
| 1716 | 0 | 1 | 281 1964 EXPERIENTIA 20(5):283-& OBBINK HJK; DALDERUP LM EFFECTS OF THALIDOMIDE ON SKELETON OF RAT FOETUS | 2 | 3 |
| 1717 | 26 | 33 | 1140 1994 EUROPEAN JOURNAL OF DERMATOLOGY 4(1):9-15 OCHONISKY S; REVUZ J THALIDOMIDE USE IN DERMATOLOGY | 29 | 34 |
| 1718 | 19 | 23 | 1118 1994 ARCHIVES OF DERMATOLOGY 130(1):66-69 OCHONISKY S; VERROUST J; BASTUJIGARIN S; GHERARDI R; REVUZ J THALIDOMIDE NEUROPATHY INCIDENCE AND CLINICOELECTROPHYSIOLOGIC FINDINGS IN 42 PATIENTS | 72 | 95 |
| 1719 | 1 | 8 | 2201 2002 HAUTARZT 53(2):150-150 Ochsendorf F; Kaufman R Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 0 | 0 |
| 1720 | 0 | 0 | 795 1982 TERATOLOGY 26(3):A19-A19 OCKENFELS H; KOCHERBECKER U; KOCHER W EFFECTS OF SINGLE AND COMBINED ACTION OF A HYDROLYSIS PRODUCT OF THALIDOMIDE AND THE SURFACTANT TWEEN 20 IN MICE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1721 | 2 | 8 | 630 1976 PHARMAZIE 31(7):492-493 OCKENFELS H; KOHLER F; MEISE W TERATOGENIC EFFECT AND STEREOSPECIFICITY OF A THALIDOMIDE METABOLITE | 4 | 9 |
| 1722 | 2 | 3 | 1362 1997 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 25(2):250-251 Odeka EB; Miller V Thalidomide in oral Crohn's disease refractory to conventional medical treatment | 17 | 0 |
| 1723 | 16 | 30 | 2620 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(6):403-409 Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy | 0 | 0 |
| 1724 | 0 | 0 | 2358 2003 BLOOD 102(11):381B-381B Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Barulli S; Capelli D; Rupoli S; Leoni P Combination therapy with Caelyx, dexamethasone and thalidomide (CDT) for multiple myeloma (MM): Preliminary results of a phase II-III study. | 0 | 0 |
| 1725 | 0 | 0 | 2595 2004 BONE MARROW TRANSPLANTATION 33:S165-S165 Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Mele A; Galieni P; Centurioni R; Alesiani F; Candela M; Leoni P Combination thalidomide, doxil and dexamethasone as salvage therapy for patients relapsed after tandem autotransplant | 0 | 0 |
| 1726 | 4 | 10 | 2463 2003 HAEMATOLOGICA 88(12):1432-1433 Offidani M; Marconi M; Corvotta L; Olivieri A; Catarini M; Leoni P Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study | 0 | 1 |
| 1727 | 0 | 0 | 1862 2001 BLOOD 98(11):311B-311B Offidani M; Mele A; Marconi M; Corvatta L; Candela M; Pieroni S; Malerba L; Rupoli S; Olivieri A; Leoni P Thalidomide plus melphalan in relapsed-refractory multiple myeloma. | 0 | 1 |
| 1728 | 0 | 0 | 460 1968 FEDERATION PROCEEDINGS 27(2):494-& OGILVIE JW; KANTOR FS EFFECT OF THALIDOMIDE ON IMMUNE RESPONSE | 4 | 4 |
| 1729 | 43 | 78 | 2548 2003 PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
| 1730 | 0 | 0 | 2354 2003 BLOOD 102(11):366B-367B Okikawa Y; Sakai A; Kuroda Y; Katayama Y; Takimoto Y; Okita H; Kimura A Analysis of the maturity of myeloma cells (plasma cells) is useful to select effective chemotherapy including thalidomide and to predict the progressive disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1731 | 9 | 19 | 2633 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(4):364-368 Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells | 0 | 0 |
| 1732 | 0 | 0 | 121 1962 LANCET 1(7228):542-& OLIVER MY THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 0 |
| 1733 | 0 | 0 | 1172 1995 ARTHRITIS AND RHEUMATISM 38(6):R10-R10 OLIVER SJ; CHENG TP; BANQUERIGO ML; BRAHN E THALIDOMIDE ANALOGS SUPPRESS RAT COLLAGEN ARTHRITIS | 1 | 2 |
| 1734 | 11 | 33 | 1452 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 15 | 31 |
| 1735 | 10 | 31 | 1526 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
| 1736 | 0 | 0 | 1402 1998 ARTHRITIS AND RHEUMATISM 41(9):S98-S98 Oliver SJ; Freeman SL; Kaplan G Thalidomide and analog CC1089 in rat adjuvant arthritis. | 0 | 0 |
| 1737 | 12 | 49 | 2165 2002 CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 7 |
| 1738 | 0 | 0 | 1492 1999 ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
| 1739 | 13 | 49 | 1696 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
| 1740 | 0 | 0 | 1493 1999 ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1741 | 5 | 12 | 1547 1999 GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
| 1742 | 8 | 14 | 328 1965 CLINICAL PHARMACOLOGY & THERAPEUTICS 6(3):292-& OLSON KB; HALL TC; HORTON J; KHUNG CL; HOSLEY HF THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN TREATMENT OF ADVANCED CANCER | 22 | 26 |
| 1743 | 3 | 23 | 1821 2001 BIOCHEMICAL PHARMACOLOGY 62(8):1081-1086 Onat D; Stahl W; Sies H Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344) | 2 | 3 |
| 1744 | 8 | 25 | 1908 2001 CLINICAL CANCER RESEARCH 7(11):3311-3313 Onn A; Tseng JE; Herbst RS Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy | 1 | 10 |
| 1745 | 0 | 0 | 1288 1996 NEUROLOGY 46(2):3015-3015 Openshaw H; Slatkin NE; Parker P Thalidomide neuropathy in bone marrow transplantation | 0 | 0 |
| 1746 | 37 | 60 | 1433 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
| 1747 | 0 | 0 | 1496 1999 ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
| 1748 | 7 | 13 | 1404 1998 ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 12 | 19 |
| 1749 | 20 | 27 | 1751 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
| 1750 | 0 | 0 | 1403 1998 ARTHRITIS AND RHEUMATISM 41(9):S108-S108 Ordi-Ros J; Cortes F; Martinez N; Montse M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1751 | 3 | 4 | 1985 2001 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952 Osman K; Comenzo R; Rajkumar SV Deep venous thrombosis and thalidomide therapy for multiple myeloma. | 44 | 57 |
| 1752 | 90 | 130 | 2159 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
| 1753 | 5 | 7 | 1077 1992 TRANSPLANTATION PROCEEDINGS 24(6):2624-2625 OSTRAAT O; EKBERG H; SCHATZ H; RIESBECK K; ERIKSSON T THALIDOMIDE PROLONGS GRAFT-SURVIVAL IN RAT CARDIAC TRANSPLANTS | 9 | 9 |
| 1754 | 0 | 0 | 1330 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PI44-PI44 OToole EA; Nasca MR; Palicharla P; West DP; Woodley DT Thalidomide increases keratinocyte proliferation and chemokine secretion in vitro | 0 | 0 |
| 1755 | 0 | 0 | 1755 2000 LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
| 1756 | 0 | 0 | 319 1965 BRITISH JOURNAL OF PREVENTIVE & SOCIAL MEDICINE 19(2):94-& OTTERLAN.A EFFECT OF THALIDOMIDE WARNING ON MEDICINE PRESCRIBED FOR PREGNANT WOMEN - ANALYSIS OF FREE MEDICINES DELIVERED TO EXPECTANT MOTHERS IN VASTERBOTTEN COUNTY OF SWEDEN DURING 1961 AND 1962 | 0 | 0 |
| 1757 | 0 | 0 | 147 1962 LANCET 2(7260):836-& OWEN R; SMITH A COR TRILOCULARE AND THALIDOMIDE | 3 | 5 |
| 1758 | 0 | 0 | 2369 2003 BLOOD 102(11):390B-390B Oyan B; Koc Y; Kars A; Turker A; Tekuzman G; Kansu E Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. | 0 | 0 |
| 1759 | 0 | 0 | 1272 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):546-546 Ozaki S; Yamana T; Kita M; Honda Y Effect of thalidomide on experimental choroidal neovascularization in pigmented rats | 0 | 0 |
| 1760 | 0 | 1 | 715 1979 TRIAL 15(9):9-& PAGE JA SUFFER THE CHILDREN - THE STORY OF THALIDOMIDE - INSIGHT-TEAM-OF-THE-SUNDAY-TIMES-OF-LONDON | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1761 | 5 | 7 | 2664 2004 LUPUS 13(6):481-482 Pagnoux C; Lutz-Zarrouk V; Michel M; Schaeffer A; Godeau B Cerebral venous thrombosis in a patient with antiphospholipid syndrome treated with thalidomide | 0 | 0 |
| 1762 | 3 | 28 | 623 1976 INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY 14(3):258-262 PALAYOOR T; RAVEENDRAN P; BATRA BK RESPONSES OF PRE-IMPLANTATION MOUSE EMBRYOS TO THALIDOMIDE EXPOSURE INUTERO | 0 | 0 |
| 1763 | 0 | 0 | 2106 2002 BLOOD 100(11):397A-397A Palladini G; Perfetti V; Obici L; Merlini G Thalidomide toxicity in patients with AL (primary) amyloidosis. | 0 | 3 |
| 1764 | 0 | 0 | 2074 2002 BLOOD 100(11):211A-211A Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. | 0 | 3 |
| 1765 | 0 | 0 | 2343 2003 BLOOD 102(11):148A-148A Palumbo A; Bertola A; Musto P; Nunzi M; De Stefano V; Callea V; Rotoli B; Petti MC; Caravita T; Lauta VM; Patti C; Bringhen S; Cavallo F; Falco P; Carella AM; Liberati AM; Boccadoro M Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. | 0 | 0 |
| 1766 | 0 | 0 | 1654 2000 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
| 1767 | 7 | 27 | 1936 2001 HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 24 | 37 |
| 1768 | 0 | 0 | 1836 2001 BLOOD 98(11):162A-162A Palumbo A; Giaccone L; Bringhen S; Cavallo F; Falco P; Rus C; Bertola A; Pileri A; Boccadoro M Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. | 0 | 4 |
| 1769 | 0 | 0 | 376 1966 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 21(2):201-& PAMPIGLI.G; QUIBELL EP EEG STUDIES IN SO-CALLED THALIDOMIDE BABIES | 0 | 1 |
| 1770 | 0 | 0 | 2305 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):286-286 Pan P; Omlin K; Rosenthal J; Padilla O; Stadecker M; Demmer L A case of Restrictive Dermopathy with survival beyond the neonatal period and novel experience with thalidomide therapy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1771 | 3 | 20 | 2511 2003 LEPROSY REVIEW 74(3):286-288 Pannikar V The return of thalidomide: new uses and renewed concerns | 0 | 1 |
| 1772 | 6 | 15 | 1994 2001 OPHTHALMOLOGICA 215(1):70-73 Parentin F; Da Pozzo S; Lepore L; Perissutti P Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child | 2 | 2 |
| 1773 | 0 | 0 | 2334 2003 ATHEROSCLEROSIS SUPPLEMENTS 4(2):28-28 Park SJ Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 1774 | 11 | 36 | 2582 2004 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24(5):885-891 Park SJ; Kim HS; Yang HM; Park KW; Youn SW; Jeon SI; Kim DH; Koo BK; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 1775 | 6 | 25 | 1175 1995 BLOOD 86(9):3604-3609 PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 51 | 85 |
| 1776 | 0 | 0 | 1122 1994 BLOOD 84(10):A335-A335 PARKER PM; NADEMANEE A; ODONNELL MR; SNYDER DS; STEIN A; SMITH E; MOLINA A; STEPAN DE; CHAO N; NILAND JC; BLUME KG; FORMAN SJ NEUTROPENIA IS A COMPLICATION OF THALIDOMIDE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 1777 | 11 | 29 | 836 1983 TERATOLOGY 27(3):327-332 PARKHIE M; WEBB M EMBRYOTOXICITY AND TERATOGENICITY OF THALIDOMIDE IN RATS | 3 | 7 |
| 1778 | 13 | 25 | 1585 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 110 |
| 1779 | 3 | 25 | 1440 1998 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 12 |
| 1780 | 4 | 5 | 346 1965 NATURE 205(4977):1241-& PARUPS EV; HOFFMAN I ABSENCE OF GROWTH EFFECTS OF THALIDOMIDE ON HIGHER PLANTS | 0 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1781 | 4 | 4 | 1886 2001 BRITISH JOURNAL OF DERMATOLOGY 144(6):1292-1293 Passeron T; Lacour JP; Murr D; Ortonne JP Thalidomide-induced amenorrhoea: two cases | 4 | 4 |
| 1782 | 27 | 38 | 1186 1995 CLINICAL INFECTIOUS DISEASES 20(2):250-254 PATERSON DL; GEORGHIOU PR; ALLWORTH AM; KEMP RJ THALIDOMIDE AS TREATMENT OF REFRACTORY APHTHOUS ULCERATION RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION | 38 | 60 |
| 1783 | 1 | 6 | 994 1989 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 13(1):104-104 PATEY O; CHARASZ N; ROUCAYROL AM; MALKIN JE; LAFAIX C THALIDOMIDE AND INTESTINAL INVOLVEMENT IN BEHCETS SYNDROME | 2 | 3 |
| 1784 | 2 | 3 | 2447 2003 DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
| 1785 | 0 | 0 | 2128 2002 BONE MARROW TRANSPLANTATION 29:S104-S104 Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients | 0 | 0 |
| 1786 | 3 | 10 | 2461 2003 HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 1787 | 0 | 0 | 2399 2003 BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 1788 | 3 | 14 | 1610 2000 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 23(3):319-321 Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide | 14 | 25 |
| 1789 | 0 | 0 | 2372 2003 BLOOD 102(11):449A-449A Patten PE; Ahsan G; Kazmi M; Fields PA; Chick GW; Jones RR; Bradwell AR; Schey SA The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). | 0 | 0 |
| 1790 | 10 | 32 | 2673 2004 MELANOMA RESEARCH 14(1):57-62 Pawlak WZ; Legha SS Phase II study of thalidomide in patients with metastatic melanoma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1791 | 0 | 2 | 2145 2002 BRITISH JOURNAL OF PHARMACOLOGY 137 Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse | 0 | 0 |
| 1792 | 0 | 0 | 1672 2000 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
| 1793 | 0 | 0 | 2084 2002 BLOOD 100(11):371B-371B Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes. | 0 | 0 |
| 1794 | 0 | 12 | 363 1966 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 47(2):186-& PEARN JH; VICKERS TH RABBIT THALIDOMIDE EMBRYOPATHY | 8 | 12 |
| 1795 | 1 | 3 | 1110 1993 PRESSE MEDICALE 22(1):37-37 PEDAILLES S; TROUSSARD X; LAUNAY V; BAZIN A; SENTIAS C; SURBLED M SCLERODERMATOUS SKIN REACTION IN GRAFT-VERSUS-HOST DISEASE TREATED WITH THALIDOMIDE | 2 | 2 |
| 1796 | 56 | 65 | 2299 2003 AMERICAN JOURNAL OF CLINICAL DERMATOLOGY 4(6):379-387 Pelle MT; Werth VP Thalidomide in cutaneous lupus erythematosus | 0 | 0 |
| 1797 | 2 | 13 | 507 1970 LANCET 1(7641):275-& PEMBREY ME; CLARKE CA NORMAL CHILD AFTER MATERNAL THALIDOMIDE INGESTION IN CRITICAL PERIOD OF PREGNANCY | 4 | 8 |
| 1798 | 7 | 32 | 2512 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
| 1799 | 3 | 5 | 1625 2000 ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
| 1800 | 14 | 35 | 2586 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(2):421-425 Perino S; Contino-Pepin C; Satchi-Fainaro R; Butterfield C; Pucci B Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties | 0 | 0 |
Page 6: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22